Daré Bioscience, Inc. (DARE)
| Market Cap | 8.01M -67.2% |
| Revenue (ttm) | 1.41M +10,429.4% |
| Net Income | -10.58M |
| EPS | -0.70 |
| Shares Out | 19.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 173,237 |
| Open | 0.4522 |
| Previous Close | 0.4520 |
| Day's Range | 0.4058 - 0.4866 |
| 52-Week Range | 0.4058 - 3.7800 |
| Beta | 1.15 |
| Analysts | Strong Buy |
| Price Target | 6.33 (+1,454.3%) |
| Earnings Date | Nov 16, 2026 |
About DARE
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor sympto... [Read more]
Financial Performance
In 2025, Daré Bioscience's revenue was $1.03 million, an increase of 10429.36% compared to the previous year's $9,784. Losses were -$13.40 million, 230.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for DARE stock is "Strong Buy." The 12-month stock price target is $6.33, which is an increase of 1,454.30% from the latest price.
News
Daré Bioscience Earnings Call Transcript: Q3 2026
Q3 revenue was ~$48,000 and net loss ~$3.2M, with ~$11.5M in cash. Commercial activity advanced for Flora Sync LF5 and DARE to PLAY, while Ovaprene and DARE-HPV progress toward 2027 readouts.
Daré Bioscience Earnings release: Q3 2026
Daré Bioscience released its Q3 2026 earnings on November 16, 2026, summarizing the period's financial results.
Daré Bioscience Quarterly report: Q3 2026
Daré Bioscience has published its Q3 2026 quarterly earnings report on November 16, 2026.
Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement
DARE to PLAY™ Sildenafil Cream prescription dispensing activities underway this month, with prescriptions written across 48 states and Washington, D.C.
Daré Bioscience Receives Approximately $852,000 in Additional Grant Funding
Additional funding represents the second-to-last anticipated payment under the up to approximately $10.7 million grant agreement supporting preclinical development of a novel non-hormonal intravaginal...
Daré Bioscience Transcript: Stifel 2026 Healthcare Conference 2026
Commercial launches are underway, with Flora Sync on market and DARE to PLAY 503B dispensing expected later in 2026. Ovaprene and DARE-HPV data are expected in 2027, supported by grant funding.
Daré Bioscience Transcript: EGM 2026
Stockholders preliminarily approved potential future share issuance upon exercise of outstanding warrants and a conditional adjournment to solicit further proxies. Final results were to include later votes and be reported in an SEC Form 8-K.
Daré Bioscience to Host Third Quarter 2026 Financial Results and Company Update Conference Call and Webcast on November 16, 2026
SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science...
Daré Bioscience Releases Next Episode in “CEO Corner” Video Series
Sabrina Martucci Johnson, Founder, President and CEO, discusses numerous potential value drivers expected to power the Company's next phase of growth and commercial success
Daré Bioscience to Present at Stifel's 2026 Healthcare Conference
SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science...
Dare Bioscience receives additional $1.5M funding installment for DARE-LARC1
Dare Bioscience (DARE) announced receipt of an additional $1.5M funding installment under its multi-year grant agreement in support of development of DARE-LARC1, an investigational long-acting reversi...
Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum
Latest $1.5 Million Installment Reflects Continued Milestone Progress as DARE-LARC1 Advances in Preclinical Development
Daré Bioscience Addresses New National Focus on Women's Health in Virtual Investor “What This Means” Discussion
Sabrina Martucci Johnson, President and CEO, shares her perspective on the recent White House Executive Order and how Daré Bioscience's growing commercial portfolio and clinical pipeline position the ...
Daré Bioscience Proxy statement: Proxy filing
Daré Bioscience filed a proxy statement on October 27, 2026, providing details for shareholder voting and corporate governance matters.
Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly
A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program
Dare Bioscience initiated with a Buy at Ladenburg
Ladenburg initiated coverage of Dare Bioscience (DARE) with a Buy rating and $2 price target
Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer
Premier sponsorship of the HERmedicine and OncoMenopause Consortium® program underscores Daré Bioscience's commitment to addressing unmet women's health needs, including for women affected by breast c...
Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company's Pipeline of Women's Health Innovations, Corporate Strategy and Opportunities
New video series featuring Founder, President and CEO Sabrina Martucci Johnson will provide investors with insights into Daré Bioscience's growing commercial portfolio, clinical pipeline and strategic...
Dare Bioscience to present Sildenafil Cream data at SMSNA meeting
Dare Bioscience (DARE) announced that clinical data from a Phase 1 study that evaluated the company’s proprietary Sildenafil Cream, 3.6% investigational product will be presented at the Annual Fall Sc...
Daré Bioscience Proxy statement: Proxy filing
Daré Bioscience filed a proxy statement on October 6, 2026, providing details for shareholder voting and corporate governance matters.
Daré Bioscience Slides: Corporate presentation
Daré Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on October 1, 2026.
Dare Bioscience announces issuance of patent for DARE-HPV program
Dare Bioscience (DARE) announced the issuance of U.S. Patent No. 12,678,439, titled “Lopinavir and Ritonavir for the Treatment of Cervix Disorders,” which covers pharmaceutical compositions formulated...
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection
Daré Bioscience Proxy statement: Proxy filing
Daré Bioscience filed a proxy statement on September 23, 2026, providing details for shareholder voting and corporate governance matters.
Dare Bioscience publishes results from Sildenafil Cream study
Dare Bioscience (DARE) announced the publication of results from a Phase 1 clinical study evaluating the safety and systemic pharmacokinetics of topical Sildenafil Cream, 3.6% in healthy adult men in…